New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Published data indicates the Prolaris Biopsy Test provides significant additional prognostic information for prostate cancer beyond conventional clinical risk categories. The update is supportive of the test’s added clinical value, though specific effect sizes, study outcomes, and market uptake details were not provided. Overall, this is a modest positive development for the company’s clinical positioning.

Analysis

Published data indicates the Prolaris Biopsy Test provides significant additional prognostic information for prostate cancer beyond conventional clinical risk categories. The update is supportive of the test’s added clinical value, though specific effect sizes, study outcomes, and market uptake details were not provided. Overall, this is a modest positive development for the company’s clinical positioning.